Cargando…
Sperm quality is not affected by the BNT162b2 mRNA SARS-CoV-2 vaccine: results of a 6–14 months follow-up
PURPOSE: We aimed to investigate the possible effect of SARS-CoV-2 vaccination on sperm quality by evaluating semen analyses of men prior to vaccination and 6–14 months after vaccination. METHODS: This was a retrospective cohort study, conducted in a university-affiliated in vitro fertilization cent...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9483282/ https://www.ncbi.nlm.nih.gov/pubmed/36114906 http://dx.doi.org/10.1007/s10815-022-02621-x |
_version_ | 1784791638880550912 |
---|---|
author | Karavani, Gilad Chill, Henry H. Meirman, Cherut Gutman-Ido, Einat Herzberg, Shmuel Tzipora, Tachover Imbar, Tal Ben-Meir, Assaf |
author_facet | Karavani, Gilad Chill, Henry H. Meirman, Cherut Gutman-Ido, Einat Herzberg, Shmuel Tzipora, Tachover Imbar, Tal Ben-Meir, Assaf |
author_sort | Karavani, Gilad |
collection | PubMed |
description | PURPOSE: We aimed to investigate the possible effect of SARS-CoV-2 vaccination on sperm quality by evaluating semen analyses of men prior to vaccination and 6–14 months after vaccination. METHODS: This was a retrospective cohort study, conducted in a university-affiliated in vitro fertilization center between October 2021 and March 2022, including men not previously infected with the SARS-CoV-2 virus who received at least 2 doses of the Pfizer-BioNTech (BNT162b2) SARS-CoV-2 vaccine. Semen analyses of samples given pre-vaccination and 6–14 months post-vaccination were analyzed for the parameters of volume, concentration, motility, morphology, and total motile count (TMC) and compared. These parameters were also compared separately for men who received a third (booster) dose and for men with pre-vaccination normal and abnormal sperm. Correlations between time from vaccination and post-vaccination sperm parameters were also assessed. RESULTS: Fifty-eight men were included in the final analysis. Semen volume (2.9 ± 1.4 vs. 2.9 ± 1.6 ml), sperm concentration (42.9 ± 37.9 vs. 51.5 ± 46.2 million/ml), motility (42.5 ± 23.1 vs. 44.3 ± 23.4 percent), morphology (8.8 ± .16.6 vs. 6.6 ± 8.8 percent), and TMC (55.7 ± 57.9 vs. 71.1 ± 77.1 million) were comparable between the pre- and post-vaccination samples. This was true for the entire study cohort, for the subgroup of men who received a third dose and for the subgroups of men with a pre-vaccination normal and abnormal semen samples. No correlation was found between time from vaccination and post-vaccination sperm parameters. CONCLUSIONS: The Pfizer-BioNTech (BNT162b2) SARS-CoV-2 vaccine does not impair any of the sperm parameters over a relatively long-time interval of 6 to 14 months from vaccination. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10815-022-02621-x. |
format | Online Article Text |
id | pubmed-9483282 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-94832822022-09-19 Sperm quality is not affected by the BNT162b2 mRNA SARS-CoV-2 vaccine: results of a 6–14 months follow-up Karavani, Gilad Chill, Henry H. Meirman, Cherut Gutman-Ido, Einat Herzberg, Shmuel Tzipora, Tachover Imbar, Tal Ben-Meir, Assaf J Assist Reprod Genet Gamete Biology PURPOSE: We aimed to investigate the possible effect of SARS-CoV-2 vaccination on sperm quality by evaluating semen analyses of men prior to vaccination and 6–14 months after vaccination. METHODS: This was a retrospective cohort study, conducted in a university-affiliated in vitro fertilization center between October 2021 and March 2022, including men not previously infected with the SARS-CoV-2 virus who received at least 2 doses of the Pfizer-BioNTech (BNT162b2) SARS-CoV-2 vaccine. Semen analyses of samples given pre-vaccination and 6–14 months post-vaccination were analyzed for the parameters of volume, concentration, motility, morphology, and total motile count (TMC) and compared. These parameters were also compared separately for men who received a third (booster) dose and for men with pre-vaccination normal and abnormal sperm. Correlations between time from vaccination and post-vaccination sperm parameters were also assessed. RESULTS: Fifty-eight men were included in the final analysis. Semen volume (2.9 ± 1.4 vs. 2.9 ± 1.6 ml), sperm concentration (42.9 ± 37.9 vs. 51.5 ± 46.2 million/ml), motility (42.5 ± 23.1 vs. 44.3 ± 23.4 percent), morphology (8.8 ± .16.6 vs. 6.6 ± 8.8 percent), and TMC (55.7 ± 57.9 vs. 71.1 ± 77.1 million) were comparable between the pre- and post-vaccination samples. This was true for the entire study cohort, for the subgroup of men who received a third dose and for the subgroups of men with a pre-vaccination normal and abnormal semen samples. No correlation was found between time from vaccination and post-vaccination sperm parameters. CONCLUSIONS: The Pfizer-BioNTech (BNT162b2) SARS-CoV-2 vaccine does not impair any of the sperm parameters over a relatively long-time interval of 6 to 14 months from vaccination. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10815-022-02621-x. Springer US 2022-09-17 2022-10 /pmc/articles/PMC9483282/ /pubmed/36114906 http://dx.doi.org/10.1007/s10815-022-02621-x Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
spellingShingle | Gamete Biology Karavani, Gilad Chill, Henry H. Meirman, Cherut Gutman-Ido, Einat Herzberg, Shmuel Tzipora, Tachover Imbar, Tal Ben-Meir, Assaf Sperm quality is not affected by the BNT162b2 mRNA SARS-CoV-2 vaccine: results of a 6–14 months follow-up |
title | Sperm quality is not affected by the BNT162b2 mRNA SARS-CoV-2 vaccine: results of a 6–14 months follow-up |
title_full | Sperm quality is not affected by the BNT162b2 mRNA SARS-CoV-2 vaccine: results of a 6–14 months follow-up |
title_fullStr | Sperm quality is not affected by the BNT162b2 mRNA SARS-CoV-2 vaccine: results of a 6–14 months follow-up |
title_full_unstemmed | Sperm quality is not affected by the BNT162b2 mRNA SARS-CoV-2 vaccine: results of a 6–14 months follow-up |
title_short | Sperm quality is not affected by the BNT162b2 mRNA SARS-CoV-2 vaccine: results of a 6–14 months follow-up |
title_sort | sperm quality is not affected by the bnt162b2 mrna sars-cov-2 vaccine: results of a 6–14 months follow-up |
topic | Gamete Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9483282/ https://www.ncbi.nlm.nih.gov/pubmed/36114906 http://dx.doi.org/10.1007/s10815-022-02621-x |
work_keys_str_mv | AT karavanigilad spermqualityisnotaffectedbythebnt162b2mrnasarscov2vaccineresultsofa614monthsfollowup AT chillhenryh spermqualityisnotaffectedbythebnt162b2mrnasarscov2vaccineresultsofa614monthsfollowup AT meirmancherut spermqualityisnotaffectedbythebnt162b2mrnasarscov2vaccineresultsofa614monthsfollowup AT gutmanidoeinat spermqualityisnotaffectedbythebnt162b2mrnasarscov2vaccineresultsofa614monthsfollowup AT herzbergshmuel spermqualityisnotaffectedbythebnt162b2mrnasarscov2vaccineresultsofa614monthsfollowup AT tziporatachover spermqualityisnotaffectedbythebnt162b2mrnasarscov2vaccineresultsofa614monthsfollowup AT imbartal spermqualityisnotaffectedbythebnt162b2mrnasarscov2vaccineresultsofa614monthsfollowup AT benmeirassaf spermqualityisnotaffectedbythebnt162b2mrnasarscov2vaccineresultsofa614monthsfollowup |